ZetrOZ Systems Announces Partnership with Arthritis Foundation to Transform Arthritis Patient Education
The developer of sustained acoustic medicine technology and the sam® wearable ultrasound device and number one resource for arthritis information will support the Foundation's efforts to provide resources and education to patients, families and caregivers.
TRUMBULL, CONNECTICUT / ACCESS Newswire / May 2, 2025 / ZetrOZ Systems and the Arthritis Foundation announce a partnership with the potential to transform pain management for the 60 million adults in the U.S. living with arthritis. ZetrOZ Systems will work with the Foundation to raise awareness of pain management and treatment options for people with osteoarthritis, the most common form of arthritis. ZetrOZ Systems will sponsor the Foundation's upcoming "Arthritis Explained" podcast and support its national support group program.
For more than 75 years, the Arthritis Foundation has been the nation's leader in advocacy, research and support for people with arthritis, a debilitating joint inflammation disease. Its mission is to drive funding for research toward a cure and new treatments for arthritis, to advocate for policies that eliminate barriers to arthritis care, and to help patients and their families find community and support through Arthritis Foundation resources.
ZetrOZ Systems, based in Connecticut, is the inventor of sustained acoustic medicine and the sam® wearable ultrasound unit. Sustained acoustic medicine is a long-duration, continuous, multi-hour, high frequency ultrasound treatment defined in 48 U.S. and global patents and that has been cleared by the U.S. Food and Drug Administration for treating soft-tissue injuries. The treatment has been proven effective in 30 Level 1-5 clinical studies for treating osteoarthritis and other conditions, and through millions of treatments provided annually to patients across the United States.
"This partnership brings together two organizations with a shared commitment to improving the lives of people living with osteoarthritis," said Beth Aulwes, Director of National Partnerships with the Arthritis Foundation. "As the leading resource of arthritis information and resources for patients, we welcome corporate partners like ZetrOZ who are committed to helping us provide education, resources and support for our patient community, including military veterans who are more likely to receive an arthritis diagnosis."
"ZetrOZ Systems is honored to stand alongside one of the most trusted voices in arthritis care as ZetrOZ Systems works toward our longtime goal to help 100 million people manage pain without the use of opioids," said George K. Lewis, founder and CEO of ZetrOZ Systems and inventor of sustained acoustic medicine.
Arthritis is one of the most prevalent diseases in the United States, affecting over one in five adults, more than are affected by diabetes, heart disease or kidney disease. The Arthritis Foundation estimates that nearly 60 million adults and hundreds of thousands of children in the U.S. are living with osteoarthritis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, or related musculoskeletal diseases.
Arthritis is also associated with dispensed opioid prescriptions and opioid use disorder, being commonly prescribed to treat pain resulting from both osteoarthritis and rheumatoid arthritis, despite questions about opioids' efficacy and potential for leading to addiction.
ZetrOZ Systems' sam® technology offers a way to treat arthritis pain without the use of potentially addictive painkillers. Sustained acoustic medicine and the sam® device work by generating continuous ultrasound waves in soft tissue, which reduces inflammation, increases blood vessel diameters, and improves blood flow. That in turn increases oxygenated hemoglobin at the site and removes cytokine enzymes and cellular waste. The result is more rapid healing and reduced pain.
Multiple studies have demonstrated the efficacy of sustained acoustic medicine in treating soft-tissue injuries, including forms of arthritis. An article published in the Journal of Orthopaedic Surgery and Research reported on a randomized, double-blind, placebo-controlled study of patients with knee osteoarthritis. The group receiving sustained acoustic medicine treatment saw significant improvements in both pain reduction and restored joint function compared to the placebo group. The authors concluded: "Long-duration low-intensity ultrasound significantly reduced pain and improved joint function in patients with moderate to severe osteoarthritis knee pain."
"By working with the Arthritis Foundation, we're building momentum for a movement toward safer, smarter, and more accessible pain management," Lewis said. "We have the opportunity to change how arthritis is understood and treated across the country."
For more information, please visit https://zetroz.com/ or https://www.arthritis.org/.
About ZetrOZ Systems ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 48 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions.
About the Arthritis FoundationThe Arthritis Foundation is fighting for all people who live with arthritis. As Champions of Yes, the Arthritis Foundation has a mission to turn the obstacles arthritis causes into opportunities. The Arthritis Foundation not only champions life-changing solutions and medical advancements, but it also provides ways for people to connect, break down barriers in health care, and join the fight to conquer arthritis - uniting hearts, minds, and resources to change the future of arthritis.
Contact Information
Catherine Hoblin Media Contactchoblin@zetroz.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
9 hours ago
- Newsweek
The Key to Better Sleep Is in Your Gut, Says Gastroenterologist
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Around 25 million U.S. adults suffer from insomnia. At the same time, more than 3.9 million Americans are taking probiotics, usually for gut health, according to the American Gastroenterological Association (AGA). And gut health could be the key to better sleep. A study published in the journal Engineering examined a specific probiotic strain called Lactobacillus helveticus CCFM1320. This probiotic produces a compound known as SAM (S-adenosylmethionine), which helps regulate the body's internal clock and supports the production of melatonin, a hormone that promotes sleep. The researchers found that this probiotic could significantly improve sleep quality. The Gut as a Second Brain Neuroscientist Dr. Chelsie Rohrscheib, the head of sleep at Wesper, a national home sleep disorder diagnostics company, told Newsweek: "The gut essentially acts as a secondary nervous system and creates and releases many crucial neurotransmitters, such as serotonin, which also help to regulate nervous system activity. "This allows for two-way communication between the gut and the brain, called the gut-brain axis. Healthy gut microbes are essential to keeping the gut healthy and functioning, and there is ample evidence that gut microbiota dysregulation can negatively impact the activity of the gut-brain axis. Because the brain is highly sensitive, this can lead to poor sleep quality." Stock image of a woman taking pills from her nightstand before bed. Stock image of a woman taking pills from her nightstand before bed. Liudmila Chernetska/iStock / Getty Images Plus Is CCFM1320 a Game-Changing Strain? To test the effectiveness of CCFM1320 in humans, scientists from Jiangnan University conducted a four-week study with 60 volunteers who experienced sleep difficulties. Participants were divided into two groups: one received the probiotic, while the other took a placebo. Results showed that those who consumed the probiotic had better sleep scores, lower levels of the stress hormone cortisol, and a healthier balance of gut bacteria. Additionally, the probiotic boosted the expression of genes involved in producing and utilizing SAM, a key factor in sleep and overall health. Strain-Specific Benefits Dr. Michel Bass, a board-certified gastroenterologist and the Founding Medical Director at Oshi Health in Philadelphia, Pennsylvania, emphasized the importance of strain specificity: "Not all probiotics are created equal. This study identified CCFM1320 as uniquely beneficial for sleep quality. This isn't a generic 'take-any-probiotic' situation—it's about strain-level specificity," Bass told Newsweek. "That's where a lot of public messaging needs to evolve. Just like different medications target different conditions, different strains do different things. And this one appears to enhance melatonin synthesis via SAM methylation—a novel pathway." Probiotic Supplements vs. Fermented Foods Stock image of an assortment of fresh vegetables and meats. Stock image of an assortment of fresh vegetables and meats. esilzengin/iStock / Getty Images Plus While fermented foods like yogurt, kimchi, and kefir are beneficial for general gut health, Bass explained that they may not provide targeted probiotic strains at therapeutic levels. "If someone wants to improve things like sleep quality or reduce stress hormones like cortisol, a strong, well-researched supplement—especially one with proven strains like CCFM1320—is usually more effective," he said. "That said, eating fermented foods is still a great daily habit and can complement targeted probiotic supplements." Jason Eastty, owner of Healthspan Longevity in Westborough, Massachusetts, and a nutrition specialist, added that overall good nutrition can combat poor sleep. "Having a nutrient deficiency—like low iron, magnesium, or vitamin D—can throw off your gut microbial balance, leading to poor sleep. Clinical trials have shown that correcting these deficiencies helps microbial diversity and improves sleep efficiency," Eastty said. He also emphasized that a whole-foods diet rich in fiber—from fruits, vegetables, legumes, nuts, seeds, and whole grains—is essential to feeding the "good" bacteria in your gut.
Tom's Guide
13 hours ago
- Tom's Guide
I'm a personal trainer who loves yoga — these are the 3 moves I stole to build my upper body and core without weights
I love yoga, and not only has weightlifting improved my ability in the yoga studio, but my yoga practice itself has actually improved my efforts in the gym. Yoga doesn't just build mobility and flexibility (which is great for your range of motion during lifts, by the way); it also improves your functional strength. Plus, yoga routines strengthen your core muscles, relying on them for stability during balances and more advanced postures, so you can harness core power, as well as become bendier on your mat and in daily life. When I fancy rolling out one of the best yoga mats for my home practice, I sometimes take yoga poses and incorporate them into a short bodyweight strengthening routine. These moves only take a short time to do, and I swear by them as a keen yogi and weightlifter for maintaining strength and suppleness. I recommend an exercise mat and a yoga block if you have one. Give these a try, and I also include a routine to help you build some structure into the exercises below. A post shared by Sam (@sam_stretchstrongco) A photo posted by on Two staples in yoga, usually connected by chaturanga. If you suffer from back pain, I would err on the side of caution with this exercise and pop your knees down onto the mat to help protect your lower back as you transition. If you experience pain, stop immediately. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. This combo move is full-body and delivers a deep stretch into the back body during downdog and the front body as you flow into updog. Move slowly and with control. Known as Utthita Parsvakonasana, the extended side angle posture strengthens your legs and core while opening up your hips and stretching the side body, hamstrings and spine. Over time, practicing holding this pose can also build balance and stability as you create a long line from ankle to fingertip. For an added challenge, see if you can extend both arms into the air. This challenges your oblique muscles that run down your waist while improving your isometric core strength. Learning how to do dolphin pose will do wonders for your upper body and shoulder strength; it's also a test of back body mobility, especially for the shoulders and hamstrings. Focus on drawing your heels down toward the mat and lifting your hips high. Check out the video above for the transitions to make this routine flow.
Business Upturn
20 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
